Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAN-300 in active rheumatoid arthritis
NCT02047604Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Dec 2013
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of voralizumab in rheumatoid arthritis (RA), sponsored by Valeant Pharmaceuticals. Started Dec 2013; status: completed.
02
Drugs
voralizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02047604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047604.